Andrea N. Lucas

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Kieron Dunleavy, Michelle A. Fanale, Ariela Noy et al. · The Lancet Haematology · 2018 · 232 citations

Medicine, Oncology, Pharmacology +11

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Mark Roschewski, Kieron Dunleavy, Jeremy S. Abramson et al. · Journal of Clinical Oncology · 2020 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, Michelle A. Fanale, Ann S. LaCasce et al. · Blood · 2014 · 55 citations

Medicine, Hematology, Oncology +9

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy et al. · Blood Advances · 2022 · 44 citations · Full text

Medicine, Hematology, Oncology +17

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Kieron Dunleavy, Catherine Lai, Mark Roschewski et al. · Blood · 2015 · 29 citations

Medicine, Oncology, Pharmacotherapy +10